4//SEC Filing
Bancel Stephane 4
Accession 0001127602-23-019319
CIK 0001682852other
Filed
Jun 22, 8:00 PM ET
Accepted
Jun 23, 4:03 PM ET
Size
20.9 KB
Accession
0001127602-23-019319
Insider Transaction Report
Form 4
Moderna, Inc.MRNA
Bancel Stephane
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2023-06-21−40,000→ 67,155 totalExercise: $0.99Exp: 2023-08-19→ Common Stock (40,000 underlying) - Exercise/Conversion
Common Stock
2023-06-21$0.99/sh+40,000$39,600→ 5,451,946 total - Sale
Common Stock
2023-06-21$121.77/sh−20,711$2,521,978→ 5,431,235 total - Sale
Common Stock
2023-06-21$122.21/sh−19,289$2,357,309→ 5,411,946 total - Sale
Common Stock
2023-06-22$119.13/sh−24,829$2,957,879→ 5,427,117 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-06-22−40,000→ 27,155 totalExercise: $0.99Exp: 2023-08-19→ Common Stock (40,000 underlying) - Exercise/Conversion
Common Stock
2023-06-22$0.99/sh+40,000$39,600→ 5,451,946 total - Sale
Common Stock
2023-06-22$119.87/sh−15,171$1,818,548→ 5,411,946 total
Holdings
- 9,050,372(indirect: See Footnote)
Common Stock
- 6,564,880(indirect: See Footnote)
Common Stock
Footnotes (8)
- [F1]These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
- [F2]These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
- [F3]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.
- [F4]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.02 to $122.01. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.03 to $122.88. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.48 to $119.48. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $119.49 to $120.41. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F8]This option is fully vested and exercisable.
Documents
Issuer
Moderna, Inc.
CIK 0001682852
Entity typeother
Related Parties
1- filerCIK 0001443340
Filing Metadata
- Form type
- 4
- Filed
- Jun 22, 8:00 PM ET
- Accepted
- Jun 23, 4:03 PM ET
- Size
- 20.9 KB